| Literature DB >> 26771848 |
Wenya Linda Bi1,2, Malak Abedalthagafi3, Peleg Horowitz1, Pankaj K Agarwalla4,2, Yu Mei1, Ayal A Aizer5, Ryan Brewster3, Gavin P Dunn6, Ossama Al-Mefty1, Brian M Alexander5, Sandro Santagata3, Rameen Beroukhim2, Ian F Dunn1.
Abstract
Meningiomas are the most common primary intracranial neoplasms in adults. Current histopathological grading schemes do not consistently predict their natural history. Classic cytogenetic studies have disclosed a progressive course of chromosomal aberrations, especially in high-grade meningiomas. Furthermore, the recent application of unbiased next-generation sequencing approaches has implicated several novel genes whose mutations underlie a substantial percentage of meningiomas. These insights may serve to craft a molecular taxonomy for meningiomas and highlight putative therapeutic targets in a new era of rational biology-informed precision medicine.Entities:
Keywords: MAPK = mitogen-activated protein kinase; NF2 = neurofibromatosis Type 2; PI3K = phosphoinositide-3-kinase; genomics; hpf = high-power field; mTOR = mammalian target of rapamycin; meningioma; molecular taxonomy; oncology; precision medicine; targeted therapy; tumor classification; tumor progression
Mesh:
Year: 2016 PMID: 26771848 DOI: 10.3171/2015.6.JNS15591
Source DB: PubMed Journal: J Neurosurg ISSN: 0022-3085 Impact factor: 5.115